"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Physostigmine Salicylate (physostigmine salicylate (injection)) Injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine).
For post-anesthesia, the concomitant use of atropine with physostigmine salicylate (physostigmine salicylate (injection)) is not recommended, since the atropine antagonizes the action of physostigmine.
Last reviewed on RxList: 11/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Physostigmine Salicylate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.